Acute myeloid leukemia is a malignancy of blood cells, and it is known as the most common type of leukemia in adults. Even after the successful treatment, the majority of patients’ health deteriorates after a period of improvement, with less than 30% of patients living 5 years after diagnosis.
Guided by the need to develop new prognostic biomarkers for this disease, researchers from the Department of Hematology of The First Affiliated Hospital, Zhejiang University School of Medicine discovered a novel gene signature, known as the ferroptosis related gene signature, that could be used for the prognosis of acute myeloid leukemia. This signature is based on the iron-dependent cell death mechanism, and researchers discovered 12 of them that correlate with patient overall survival.
Based on the presence of the ferroptosis gene signatures, patients were divided into high- and low-risk groups, with the high-risk group having these markers previously exhibited, which was proven to reduce overall survival in comparison to the low-risk group. Gene signatures were closely linked to the reduced effectiveness of medicine for these patients.
In conclusion, ferroptosis related gene signatures are promising candidates for disease prognosis, and their discovery could lead to novel approaches to the treatment of acute myeloid leukemia.
Reference: Huang X, Zhou D, Ye X, Jin J. A novel ferroptosis-related gene signature can predict prognosis and influence immune microenvironment in acute myeloid leukemia. Bosn J of Basic Med Sci [Internet]. 2021Nov.16 [cited 2021Dec.5];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6274
Editor: Merima Bukva